IDENTIFICATION OF ANTI-CANCEROUS DRUGS FOR THE MUTATED SNAP25 PROTEIN RELATED TO BRAIN TUMOR THROUGH STRUCTURE-BASED VIRTUAL SCREENING APPROACH
DOI:
https://doi.org/10.22159/ijms.2023.v11i2.47146Keywords:
Anti-cancer, CADD, Drug Discovery, SBVS, AutodockAbstract
Objective: Brain tumor is a formidable challenge for drug development, and drugs derived from many advanced technologies are being tested in clinical trials. Synaptosomal-associated protein of 25 kDa (SNAP25) is a membrane-binding protein in neurons and it is critical in neurotransmission for the fusion of plasma membrane and synaptic vesicle making it a prime target to address brain tumors. The SNAP-25 gene is responsible for personality disorders, schizophrenia, attention deficit, and hyperactivity disorder in human beings. It is recently discovered, that this protein is responsible for brain cancer as well.
Methods: In the present research, 17 investigational and experimental anticancer drugs were selected from the PubChem and DrugBank databases to identify potential inhibitors with high stability to treat mutated SNAP25 protein. For this purpose, we have used the structure-based virtual screening technique wherein, the candidate molecules are computationally docked into the 3D structure of the biological. The docking was achieved in PyRx 0.8 software and the drugs were then ranked based on their predicted binding affinity or complementarity to the binding site.
Results: Based on the ligand binding energy, the top six compounds having greater inhibitory effects towards SNAP25 were selected and then visualized with Pymol and Biovia visualizers. The compound Crenolanib has better pharmacological properties and demonstrated higher binding affinities with the target protein. Therefore, this Crenolanib docked confirmations were appraised for molecular dynamic simulations.
Conclusion: The study concluded that the anticancer drug Crenolanib exerted inhibitory potential against the mutated protein SNAP-25 and therefore it can be exploited as a cancer modulator to address brain tumors.
References
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
Smith MA, Reaman GH. Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am 2015;62:301-12.
Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, et al. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell 2016;29:508-22.
Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm. J Clin Oncol 2007;25:2306-12.
Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32:520-37.
Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017;31:326-41.
Gilbertson RJ. Mapping cancer origins. Cell 2011;145:25-9.
Xia L, Su X, Shen J, Meng Q, Yan J, Zhang C, et al. ANLN functions as a key candidate gene in cervical cancer as determined by integrated bioinformatic analysis. Cancer Manag Res 2018;10:663-70.
Yuan L, Zeng G, Chen L, Wang G, Wang X, Cao X, et al. Identification of key genes and pathways in human clear cell renal cell carcinoma (ccRCC) by co-expression analysis. Int J Biol Sci 2018;14:266-79.
Aissouq AE, Toufik H, Stitou M, Ouammou A, Lamchouri F. In silico design of novel tetra-substituted pyridinylimidazoles derivatives as c-jun N-terminal kinase-3 inhibitors, using 2D/3D-QSAR studies, molecular docking and ADMET prediction. Int J Pept Res Ther 2020;26:1335-51.
Song CM, Lim SJ, Tong JC. Recent advances in computer-aided drug design. Brief Bioinform 2009;10:579-91.
Macalino SJ, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Arch Pharm Res 2015;38:1686-701.
Gangwal RP, Dhoke GV, Damre MV, Khandelwal K, Sangamwar AT. Structure-based virtual screening and molecular dynamic simulation studies to identify novel cytochrome bc1 inhibitors as antimalarial agents. J Comput Med 2013;2013:637901.
Srinivasan P, Perumal PC, Sudha A. Discovery of novel inhibitors for Nek6 protein through homology model assisted structure based virtual screening and molecular docking approaches. ScientificWorldJournal 2014;2014:967873.
Wang Y, Han R, Zhang H, Liu H, Li J, Liu H, et al. Combined ligand/structure- based virtual screening and molecular dynamics simulations of steroidal androgen receptor antagonists. BioMed Res Int 2017;2017:3572394.
Wang W, Wan D, Liao D, Peng G, Xu X, Yin W, et al. Identification of potent chloride intracellular channel protein 1 inhibitors from traditional Chinese medicine through structure-based virtual screening and molecular dynamics analysis. BioMed Res Int 2017;2017:4751780.
Liu Z, Zhao J, Li W, Wang X, Xu J, Xie J, et al. Molecular docking of potential inhibitors for influenza H7N9. Comput Math Methods Med 2015;2015:480764.
Dubey R, Tewari AK, Singh VP, Singh P, Dangi JS, Puerta C, et al. Molecular docking study of conformational polymorph: Building block of crystal chemistry. ScientificWorldJournal 2013;2013:309710.
Zhang D, Hu Y, Sun Q, Zhao J, Cong Z, Liu H, et al. Inhibition of transforming growth factor beta-activated kinase 1 confers neuroprotection after traumatic brain injury in rats. Neuroscience 2013;238:209-17.
Guo C, Zhuang Y, Chen Y, Chen S, Peng H, Zhou S. Significance of tumor protein p53 mutation in cellular process and drug selection in brain lower grade (WHO grades II and III) glioma. Biomark Med 2020;14:1139-50.
Huang Q, Lian C, Dong Y, Zeng H, Liu B, Xu N, et al. SNAP25 Inhibits glioma progression by regulating synapse plasticity via GLS-mediated glutaminolysis. Front Oncol 2021;11:698835.
UniProt Consortium. UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res 2019;47:D506-15.
Roy A, Kucukural A, Zhang Y. I-TASSER: A unified platform for automated protein structure and function prediction. Nat Protoc 2010;5:725-38.
Bendl J, Stourac J, Salanda O, Pavelka A, Wieben ED, Zendulka J, et al. PredictSNP: Robust and accurate consensus classifier for prediction of disease-related mutations. PLoS Comput Biol 2014;10:e1003440.
Yuan S, Chan HC, Hu Z. Using PyMOL as a platform for computational drug design. WIREs 2017;7:e1298.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: A major update to the drug bank database for 2018. Nucleic Acids Res 2018;46:D1074-82.
Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res 2021;49:D1388-95.
Tian S, Wang J, Li Y, Li D, Xu L, Hou T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev 2015;86:2-10.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
Dallakyan S, Arthur JO. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015;1263:243-50.
BIOVIA-Scientific Enterprise Software for Chemical Research. Material Science R&D; 2020. Available from: https://www.3dsbiovia. com [Last accessed on 2022 Dec 27].
Lilkova E. The PyMOL Molecular Graphics System, Version 2.2.0. New York: Schrodinger LLC; 2015.
Hollingsworth SA, Dror RO. Molecular dynamics simulations for all. Neuron 2018;99:1129-43.
Ramachandran GN, Ramakrishnan C, Sasisekharan V. Stereochemistry of polypeptide chain configurations. J Mol Biol 1963;7:95-9.
Published
How to Cite
Issue
Section
Copyright (c) 2023 SAMEER SHARMA
This work is licensed under a Creative Commons Attribution 4.0 International License.
